Aug 7 (Reuters) - Bausch Health Companies Inc BHC.TO BHC.N :
* BAUSCH HEALTH CEO SAYS NEW EYE DRUG LUMIFY ACHIEVED 21 PERCENT MARKET SHARE IN REDNESS RELIEVER CATEGORY- CONF. CALL
* BAUSCH HEALTH SAYS SINCE THE FIRST QUARTER 2016, HAVE REDUCED THE COMPANY'S DEBT BY ABOUT $7 BILLION- CONF CALL
* BAUSCH HEALTH SAYS XIFAXAN SALES $294 MILLION IN THE QUARTER, UP 26 PERCENT OVER Q2 OF 2017 - CONF CALL
* BAUSCH HEALTH SAYS WILL CONTINUE TO USE AVAILABLE CASH TO REPAY DEBT- CONF CALL
* BAUSCH HEALTH SAYS DERMATOLOGY BUSINESS CONTINUES TO FACE CHALLENGES FROM AGGRESSIVENESS OF THIRD-PARTY PAYERS AND FROM THE LIMITING OR BLOCKING OF REIMBURSEMENTS - CONF CALL
* BAUSCH HEALTH SAYS EXPECTING VYZULTA ACCESS TO MEDICARE PART D IN 2019 - CONF CALL
* BAUSCH HEALTH SAYS COMPLETED 6 REFINANCING TRANSACTIONS, RAISING TOTAL OF MORE THAN $16 BILLION IN TERM LOANS, UNSECURED BONDS AND SECURED BONDS - CONF. CALL
* BAUSCH HEALTH SAYS NOT GOING TO TAKE ANY PRICE INCREASES ON U.S. BRANDED PRESCRIPTION DRUGS FOR REST OF THE YEAR- CONF. CALL
* BAUSCH HEALTH SAYS INTERNATIONAL PHARMA BUSINESS IS AN AREA OF FOCUS, NOT SATISFIED WITH PERFORMANCE IN SOME GEOGRAPHIES- CONF. CALL
* BAUSCH HEALTH SAYS WILL KEEP OUR PRICING TO SINGLE DIGIT PRICING- CONF. CALL
* BAUSCH HEALTH SAYS ABOUT 47 PERCENT OF BUSINESS NOT EXPOSED TO PRICING PRESSURES- CONF. CALL